/

FDMT

4D Molecular Therapeutics, Inc.Open

12.34−0.66 −5.12%USD

NasdaqGS · as of Oct 13, 15:49 ET · 15m delay

Open

12.91

Prev close

13.00

Day range

12.2912.91

52-week range

6.9616.93

Volume

651.10K0.70×

Mkt cap

681.44M

P/E ttm

—

Fwd P/E

-3.01

EPS ttm

-2.70

Div yield

0.00%

Earnings

—

From 52w high

−27.14%

Price Chart

Yahoo Finance · delayed

FDMTOct 13, 2026O 12.91H 12.91L 12.29C 12.34−0.66 (−5.12%)Vol 651.10K

SMA 5013.79
SMA 20010.58

1Y change +38.60% since Oct 10, 2025 close540 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

FDMT 4D Molecular Therapeutics, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −1.79%
1 month: −6.34%
3 months: +5.43%
6 months: +27.69%
Year to date: +64.47%
1 year: +27.56%

Valuation & ownership

Market cap: 681.44M
Enterprise value: 396.06M
P/E (ttm): —
Forward P/E: -3.01
PEG ratio: —
Price / book: 1.67
Price / sales (ttm): 7.41
EV / EBITDA: -2.10
EPS (ttm): -2.70
EPS (forward): -4.09
Beta (5y monthly): 2.74
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 55.24M
Float: 42.55M
Short % of float: 23.32%
Short ratio (days): 11.58
Held by insiders: 2.72%
Held by institutions: 106.08%
Avg volume (3m): 932.84K
50-day average: 13.75
200-day average: 10.55
52-week change: +27.56%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): 37.2
vs 50-day SMA: −10.56%
vs 200-day SMA: +16.63%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▼ below
ATR (14) % of price: 7.23%
Realised vol (20d, ann.): 54.0%
From 52-week high: −27.14%
From 52-week low: +77.23%

ANR

Analyst Consensus

11 analysts

Consensus

Strong buy

1.33 on a 1 (strong buy) – 5 (sell) scale

Mean target

28.09

+127.73% implied

Low 18.00Median 28.00High 37.00

Recommendation trend

Now11 / 1 / 0
1m ago / 1 /

DES

About 4D Molecular Therapeutics, Inc.

Yahoo Finance profile

4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. It is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geographic atrophy; and 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Otsuka Pharmaceutical Co., Ltd. The company was founded in 2013 and is headquartered in EmeryVille, California.

Sector: Healthcare
Industry: Biotechnology
Employees: 196
Headquarters: EmeryVille, CA, United States
Website: 4dmoleculartherapeutics.com
Officers: Dr. John F. Milligan Ph.D. Executive Chairman
Dr. David H. Kirn M.D. Co-Founder, President, CEO & Director
Mr. Kristian Humer M.B.A. CFO and Principal Financial & Accounting Officer

SEAS

Seasonality · FDMT

2020–2026 · monthly returns

Strongest month Nov +38.50%Weakest month May −11.62%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	18.1	9.0	-3.6	-4.7	11.7	34.2	-23.5	38.6	1.4	-13.8			+64.5%
2025	0.5	-19.1	-28.7	4.3	7.4	2.5	21.3	36.9	41.1	32.3	1.4	-35.7	+34.6%
2024	-14.9	62.4	13.7	-24.9	0.2	-12.4	-15.5	-15.3	-28.0	-25.9	-2.1	-29.0	−72.5%
2023	-5.2	-8.6	-10.7	4.8	1.9	-1.6	1.3	-11.0	-21.8	-15.6	18.4	59.3	−8.8%
2022	-28.0	-13.3	10.4	-21.2	-36.3	-8.0	34.7	-16.4	2.3	7.7	179.1	-8.1	+1.2%
2021	2.2	-0.9	3.3	-10.8	-31.4	-9.3	3.3	22.8	-11.7	-10.9	-4.3	-4.6	−47.1%
2020													—

INSD

Insider Activity · FDMT

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

71.9K shares

Sells, 6 months

421.9K shares

Net shares

−350K

Net change in insider shares

−18.90%

Date	Insider	Transaction	Shares	Value
Oct 4, 2026	Kirn DavidChief Executive Officer	Sale at price 12.92 - 13.61 per share.	58.3K	$753.94K
Sep 15, 2026	Bizily ScottOfficer	Sale at price 13.65 per share.	1.6K	$22.32K
Sep 15, 2026	Bizily ScottOfficer	Conversion of Exercise of derivative security at price 4.14 per share.	1.6K	$6.77K
Sep 13, 2026	Kirn DavidChief Executive Officer	Sale at price 13.90 per share.	58.3K	$811.00K
Aug 31, 2026	Bizily ScottOfficer	Sale at price 14.00 per share.	584	$8.18K
Aug 31, 2026	Bizily ScottOfficer	Conversion of Exercise of derivative security at price 6.49 per share.	584	$3.79K
Aug 18, 2026	Kirn DavidChief Executive Officer	Sale at price 15.36 - 16.42 per share.	69.1K	$1.09M
Aug 18, 2026	Kirn DavidChief Executive Officer	Conversion of Exercise of derivative security at price 4.14 per share.	50K	$207.00K
Aug 16, 2026	Bizily ScottOfficer	Sale at price 12.00 - 12.20 per share.	3.3K	$39.57K
Aug 16, 2026	Bizily ScottOfficer	Conversion of Exercise of derivative security at price 4.14 per share.	3.3K	$13.54K
Aug 3, 2026	Kirn DavidChief Executive Officer	Sale at price 10.23 per share.	26.8K	$274.60K
Aug 2, 2026	Kirn DavidChief Executive Officer	Sale at price 10.05 per share.	12.4K	$124.72K
Jul 9, 2026	Kirn DavidChief Executive Officer	Sale at price 12.01 - 12.87 per share.	58.3K	$737.41K
Jun 29, 2026	Bizily ScottOfficer	Sale at price 14.00 per share.	6.6K	$91.92K
Jun 29, 2026	Bizily ScottOfficer	Conversion of Exercise of derivative security at price 4.14 - 6.49 per share.	6.6K	$40.70K
Jun 22, 2026	Bizily ScottOfficer	Sale at price 12.00 per share.	9.8K	$117.72K
Jun 22, 2026	Bizily ScottOfficer	Conversion of Exercise of derivative security at price 4.14 per share.	9.8K	$40.61K
Jun 21, 2026	Kirn DavidChief Executive Officer	Sale at price 10.47 per share.	114.7K	$1.20M
May 31, 2026	Kirn DavidChief Executive Officer	Sale at price 10.02 per share.	1.9K	$19.26K
Mar 19, 2026	Gupta AshooOfficer	Sale at price 8.61 per share.	390	$3.36K

13F

Investors Holding FDMT

latest 13F filings of 29 followed managers

Investors holding FDMT
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$8.2M	0.01%	614.57K	+6.3%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

FDMT

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

FDMT

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About 4D Molecular Therapeutics, Inc.

Seasonality · FDMT

Insider Activity · FDMT

Congress Trades · FDMT

Investors Holding FDMT

Investors Holding FDMT

Congress Trades · FDMT

Seasonality · FDMT

Insider Activity · FDMT

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About 4D Molecular Therapeutics, Inc.

Financial Snapshot

Earnings & Dividends

News